CD276 and brain neoplasm: Currently, there are three ongoing CD276 clinical trials: NCT04691713 is recruiting patients with advanced CD276-positive solid tumors; NCT04432649 is a Phase 2 study investigating the activity of 4SCAR-276 CAR T cells in brain tumors and Ewing sarcoma; NCT04185038 is a Phase I clinical trial for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and recurrent or refractory pediatric central nervous system tumors.